De Pardieu has advised Acteon Group, a leading manufacturer of dental products and medical devices and majority stake of the family investment holding company DENTRESSANGLE, on the signing of an agreement with Septodont, a French pharmaceutical and medical devices company, to become shareholders of Inibsa, a Spanish-based pharmaceutical group specializing in the manufacture of products for dental practitioners.
Septodont will be the controlling shareholder of Inibsa, while Acteon Group will be a partner and reference shareholder, aiming to secure and develop the existing supply relationship with the Spanish laboratory. Septodont will hold 51% of the shares, while the remaining 49% will be held by Acteon Group.
De Pardieu’s team comprised Cédric Chanas (partner), Alix Amaury and Chloé Duval (associates) on the corporate aspects, Priscilla van den Perre (partner) and Mickaël Ammar (associate) on the tax aspects, and Laetitia Gavoty Tolot (partner) and Antoine Guérin (associate) on the competition law aspects.
Other advisors:
- Septodont has been advised by Dentons.
- Acteon has been advised by Gomez-Acebo & Pombo on the Spanish law aspects.
- Inibsa and the sellers have been advised by Baker McKenzie